Sequenom Seeks Rehearing En Banc

18 August 2015 PharmaPatents Blog

Sequenom, Inc. has filed a petition for rehearing en banc of the Federal Circuit decision that held its diagnostic method claims invalid under 35 USC § 101. (You can read my synopsis of that decision here). Stakeholders in the diagnostic and personalized medicine space will be watching to see if the court grants the petition and reaches a different decision on the merits. 

The Question For En Banc Review

The petition asserts that the case “raises the following precedent-setting question of exceptional importance:

Is a novel method patent-eligible under §101 where: (1) a researcher is the first to discover a natural phenomenon; (2) that unique knowledge motivates her to apply a new combination of previously known techniques to the phenomenon; and (3) she thereby achieves a previously unknown and impossible result?

The petition summarizes the panel decision as holding that “the person who first discovers a natural phenomenon can never obtain a patent on any practical application of that new knowledge, however surprising or revolutionary the results, unless the steps she teaches to use it are independently novel,” and asserts that it “cannot be correct.”

The Contrary Precedent

The petition asserts that the panel decision is contrary to the following Supreme Court decisions:

  • Diamond v. Diehr, 450 U.S. 175 (1981), because the “Court held that a new combination of steps leading to a new practical result is eligible for a patent even if the individual steps were known beforehand and the core of the invention is an unpatentable natural law or formula.”
  • Mayo v. Prometheus Laboratories, 132 S. Ct. 1289 (2012), because it reaffirmed the principles of Diehr.
  • Association for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107 (2013), because the Court stated that “Myriad was in an excellent position to claim applications of that knowledge” of BRCA genes associated with breast cancer.

According to the petition, the natural phenomenon the Sequenom inventors discovered “motivated them to teach a new method that no one was practicing, and whose combined steps were in fact the opposite of the ‘conventional’ approach [which discarded the serum sample at issue], even if each individual technique involved was ‘well-understood’ on its own.”

Dire Consequences For Medical Inventions

The petition emphasizes the far-reaching and “dire consequences” of the panel decision, asserting that even methods of treatment are not safe from its holding:

Mayo clearly suggested that “a new way of using an existing drug” would be eligible for patent protection under §101. …. But under the panel’s test, that cannot be true: The drug is known, the means of administering it are known, and the only new insight is the (unpatentable) natural law that the drug treats a disease no one previously knew it treated.

The petition explains that under Diehr, methods of treatment are patentable because they involve “non-routine and non-conventional uses of known techniques to accomplish new results that are motivated by an insight about the natural world.” In contrast, the petition alleges, the panel decision would invalidate patents to such important methods as methods of vaccinating against Ebola virus and methods of diagnosing cancer.

The petition argues that, instead of promoting freer access to “fundamental discoveries” the fall-out from the panel decision will be to encourage inventors to keep their discoveries secret and to discourage investment.

The petition concludes by urging the full Federal Circuit to “take this opportunity to protect patent law’s fundamental principles from being eroded by results neither the Supreme Court nor Congress could possibly have intended.”

Will The Federal Circuit Grant Rehearing En Banc?

The Federal Circuit denies far more petitions for rehearing en banc than it grants, but if the court understands the significance of this case–and the potential implications of the panel decision–it might be willing to take another look, and perhaps decide that the Sequenom claims fall on the Diehr side of the patent eligibility divide.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights

Hatch Comments on DNC-Related Construction Projects in Milwaukee
14 June 2019
Milwaukee Business Journal
Bernard Quoted on Debt-Relief Settlement with ITT Tech Lender
14 June 2019
Wall Street Journal
Dodd and Daughter Profiled in Wisconsin Golf
13 June 2019
Wisconsin Golf
Brinckerhoff Comments on SCOTUS Ruling in Patent Case
11 June 2019
Intellectual Property Magazine
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ
Foley's Government Contracts Annual Update
16 October 2019
Liviona, MI